


Immunotoxicology Specialty Section Newsletter



IMMUNOTOXICOLOGY SPECIALTY SECTION



2011 - 2012 Executive Committee

President
Dr. Rodney R. Dietert

Vice President
Dr. Greg Ladics

Vice President-Elect
Dr. Gary Burleson

Secretary-Treasurer
Dr. Susan McKarns

Past President
Dr. Leigh Ann Burns Naas

Senior Councilor
Dr. Kazuichi Nakamura

Junior Councilor
Dr. Jean Pfau

PostDoc Representative
Dr. Teri Girtsman

Student Representative
* Position Open

The ImTox SS Newsletter is published 3 times/year (May, September and January). If you would like to share a book review, meeting report, interesting web site or any other item of interest with members of the Specialty Section, please send it to us by the middle of the month preceding the planned publication date. All comments on, or suggestions for, the newsletter are welcome.

Communications Committee Co-Chairs
Haley Neff-LaFord, PhD:
hnlaford@seagen.com
Ashwini Phadnis:
phadnis@msu.edu

Typesetting / desktop publishing provided by
L. Peyton Myers, Ph.D.

President's Message

Rodney Dietert, Ph.D.

I hope that your holiday season has been filled with useful reflections, joy and visions of a wonderful 2012. This newsletter message will be uncharacteristically brief, yet will target some areas for possible attention.



Dr. Rodney Dietert
President, ImTox SS
2011-2012

Preparations for San Francisco and San Antonio

As we usher in the new year I would encourage you to finalize any nominations of students, postdocs, and colleagues that might still be open for SS and SOT awards and send Gary Burleson and the Program Committee your best ideas for symposia, workshops, round tables and continuing education courses for the 2013 meeting in San Antonio. Planning ahead is very useful to ensure that our best work is on display and given appropriate recognition in both San Francisco and San Antonio.

Our ImTox SS reception at SOT in San Francisco has been scheduled for Tuesday evening from 6:00PM-7:30PM. I hope to see as many of you as is possible at this event.

The New Terrain of Immunotoxicology

The current year 2011-12 continues to be one of a tangible repositioning of the landscape of immunotoxicology within the biomedical and health-associated communities. This shift stems from a combination of both previously-planned activities and more recent developments. Regardless of the nature of your own personal work related to immunotoxicology (fundamental research, safety assessment, immunopharmacology, education, risk assessment, regulatory review, etc.), the implications of your work just got a type of free upgrade. Of course, there are no assurances that this "significance of your work" upgrade will be automatically reflected in your next paycheck.

President's Message	page 1
Committee Updates	page 2 - 4
SOT 2012 Program Updates	page 5
ImTox SS Financial Reports (current and prior years)	pages 6 - 7
Advertisements/Announcements	page 8
Articles of Interest	page 9

At the core of this sea change is a shift from a more historic view of: 1) immunotoxicology as calibration and organization of measureable immune endpoints that have generalized health implications to 2) immunotoxicology as a priority benchmark for determining the risk of quite specific and numerous major diseases and conditions. In particular, this includes the arena of non-communicable chronic diseases. The reason the linkage between immunotoxicity and chronic diseases is garnering increased attention is that chronic diseases are the leading cause of death worldwide. Additionally, the cost of chronic diseases is expected to reach a staggering 48% of the global gross domestic product by the year 2030 (World Economics Council and the Harvard School of Public Health). Last month's STEP Symposium broadcast across the National Institutes of Health set a template for the connection between immunotoxicity, immune dysfunction, inflammatory misregulation and chronic diseases across the various grant panels and the associated biomedical research

communities connected to the NIH. This symposium preceded a soon-to-be-released book (Springer) on the same topic that is notable in that the disease-specific chapters of the book were authored by a preponderance of non-immunotoxicologists. Therefore, the immunotoxicity-specific disease connection has rippled well beyond our SS and SOT to the broader scientific community. Next spring's SOT-cosponsored CCT meeting, ppTOX III, in Paris includes an opening-day session chaired by Dr. Paige Lawrence that focuses on early life environmental exposures and life-long immunological programming. It is likely to expand our new immunotoxicology terrain even further.

A Distinctive Honor

One of our ImTox SS members, Dr. Ian Kimber, recently received an honor that, to my knowledge, is a first among immunotoxicologists. At Queen Elizabeth II's most recent birthday, Dr. Kimber had bestowed upon him the honor of the Order of the British Empire (OBE). The OBE

is a title awarded across the sciences, arts, humanities, humanitarian, and public service arenas for a select subset of individuals who have made extraordinary achievements benefitting society. This highly-selective group of notable individuals is drawn from across Great Britain and the Commonwealth countries based on their remarkable career accomplishments. Dr. Kimber joins other OBE-titled toxicologists such as Drs. Philip Routledge, Andrew Renwick, Roy Goulding, Tim Marrs, Alan Boobis and Len Levy. Other 2011 awardees who joined Dr. Kimber in this special recognition included: Colin Firth - actor, Dr. David William Roger Thackray - Head of Archaeology, National Trust, Ian Robert Whitting - HM Ambassador to Iceland, and Ms Elizabeth Ann MacGregor - Director, Museum of Contemporary Art, Sydney, Australia.

I invite you to join me in offering three cheers to Ian for this well-deserved and distinguished career honor.

Rodney Dietert

Regulatory Update

Submitted by: Peter Thomas, Regulatory Subcommittee Chair.

The following regulatory updates may be of interest to the Specialty Section Membership.

According to the California Department of Toxic Substances Control, Immunotoxicity was included as one of nine specific hazards listed in an "informal draft" Safer Consumer Products regulation that would use a 0.01% hazard threshold. The others were carcinogenicity, developmental toxicity, reproductive toxicity, endocrine toxicity, genotoxicity, neurotoxicity, bioaccumulation, or environmental persistence. This hazard threshold is lower than the current generally applied 0.1% level used under United Nations Globally Harmonized Systems for classification, where immunotoxicity does not have a specific hazard classification.



A request (via the Federal Register Vol. 76, No. 224) for public comments was issued by National Institute of Environmental Health Sciences and the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods as they look to update their Five-Year Plan (current plan runs 2008-2012). They specifically mentioned immunotoxicity as a priority testing area

Recently, the EMA published a concept paper that will be used to draft the revision for the Guideline on Similar Biological Medicinal Products Containing Biotechnology Derived Proteins as Active Substance: Non-clinical and Clinical Issues (CHMP / BMWP/42832/2005). This guideline describes the nonclinical and clinical requirements for a biological medicinal product claiming to be similar to another one already marketed and came into effect in 2006. Since then, the development of biosimilar products has increased significantly and the regulatory framework is becoming larger. The comment period deadline is 31 December 2011. The draft guideline is expected to be published in 2012. Website: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/10/WC500115611.pdf

The International Conference on Harmonization (ICH) Steering Committee hosted a meeting with its working groups in Seville, Spain from 05 November – 10 November 2011. The revised “ICH S2(R1) Guideline for genotoxicity testing and data interpretation for medicines intended for human use” received approval. Website: <http://www.ich.org/ichnews/press-releases/view/article/ich-steering-committee-seville-spain-9-10-november-2011-1.html>

The FDA recently published a guidance document on integrating study results to assess concerns about reproductive and developmental toxicity. This new FDA guidance outlines a process to estimate developmental or reproductive risks associated with a new drug when there is a non-clinical toxicity finding but no definitive human data. While immunotoxicity is not considered one of the four major manifestations of developmental immunotoxicity, it may play a role in a weight of evidence approach to risk assessment. Website: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079240.pdf>

Student and Postdoctoral Report



Submitted by: Teri Girtsman, Postdoctoral Representative

Greetings to all student and postdoctoral members of the ImTox SS! I hope that the approaching New Year finds you with an abundance of wonderful science to share at the upcoming SOT Annual meeting March 6-10 in San Francisco, the beautiful city by the bay.

A reminder to the graduate students the Student Advisory Council (SAC) has been restructured as the Graduate Student Leadership Committee (GSLC). The GSLC is comprised of an executive board and three subcommittees (communications, professional development, and programming) that are comprised of the graduate student reps for special sections, special interest groups, and regional chapters. If you have any ideas that would be beneficial for your career development or activities for the annual meeting, feel free to contact me so that I may relay your thoughts to the executive board!

Congratulations to the newly minted postdoctoral fellow Jenna Benson Ph.D. who successfully defended her dissertation at the University of Montana on

December 9. Thank you for the service you provided the ImTox SS as the student rep this year! To this end, we are now in search for a student representative to fill the spot left behind by Dr. Benson. For those interested in this position, please send your CV, a brief letter describing your research goals, and a nomination letter from your advisor to Dr. Rodney Reynolds Dietert (rrd1@cornell.edu). You should first verify with your advisor that he/she is willing to fund your travel to SOT for the next two years. Please do not hesitate to contact former student rep, Jenna Benson (jenna.benson@umontana.edu) or Teri Girtsman (teri.girtsman@umontana.edu) for

more information about serving as a student representative.

We would like to thank the SOT for making available – “K99-R00 GRANTS: Tips from the NIEHS Administrator, the Grantee and the Reviewer”, Postdoctoral Assembly Web Seminar that took place on October 31st. It was well attended and extremely helpful to develop strategies to prepare for successful NIH grant submission and ultimately successful funding. The slides are available on “toXchange” at <http://www.toxicology.org/ai/spd/PD/seminarOct11.asp>.


Don’t miss the opportunity to socialize at the 2012 meeting in San Francisco (details to follow)!

I look forward to meeting you at the 2012 mixer. Come kick back and relax with fellow ImTox SS students and postdocs. It’s guaranteed to be a good time! Any and all suggestions about this or other types of student/postdoc events are welcome. Don’t hesitate to contact me (Teri Girtsman PDR).

Again, we would like to thank you for this opportunity to serve you. Please let us know about any concerns or suggestions you may have on how the ImTox SS can best assist you as immunotoxicology students and postdoctoral fellows! I look forward to hearing from you!

Postdoctoral Representative, Teri Alyn Girtsman Ph.D.

IMMUNOTOXICOLOGY SPECIALTY SECTION



**Don't forget:
ImTox SS Reception**

At the time of publication, the ImTox SS reception is scheduled for the evening of **Tuesday March, 13**.

Please check the final SOT Program for final location.

The International Exchange Committee (IEC) is pleased to announce that the invited JSIT representative for San Antonio, 2013 - Dr. Hirohisa Takano (Environmental Health Division, Department of Environmental Engineering, Graduate School of Engineering, Kyoto University and Past Director at the Environmental Health Sciences Division, National Institute for Environmental Studies - and Dr. Jean Pfau (Idaho State University, Pocatello, ID) are putting together a Symposium on “Global/Local Environmental Changes and Immune Alteration”. We look forward to this and continuing future jointly chaired sessions generated by members of both of our societies.

The IEC is also pleased to announce that one IMTOX SS member would speak at the upcoming JSIT 2012 meeting to be held at the Jikei University School of Medicine, Tokyo, in September (9/15-16/12). Based on the meeting’s theme of “New Frontiers in Immunotoxicology”, Dr. Henk van Loveren has been invited to speak to the JSIT membership on this very important topic. To see all of the presentations at the upcoming meeting, as well as to see presentation topics and pix from all past meetings (including of our former attendees), please go to the JIST site at <http://www.immunotox.org/english/index.html>.

SOT 2012 Program Updates

Submitted by: *Greg Ladics*

From Greg Ladics:



The Immunotoxicology Specialty Section will be well represented at the 2012 meeting in San Francisco with a total of 7 sessions (2 CE courses, 3 symposia and 2 workshops). These sessions include the following:

CE Course entitled “Overview and Application of the WHO/IPCS Harmonized Guidance for Immunotoxicity Risk Assessment for Chemicals”; Chairs- Andrew Rooney and Henk van Loveren

CE Course entitled “Innate Immunity and Its Relevance to Toxicology”; Chairs – Wendy Freebern and Jacintha Shenton.

Symposium - “The Allergenicity and Immunomodulatory Effect of Food Substances”; Chairs- Greg Ladics and Reiko Teshima

Symposium - “The Role of Danger Signals in the Development of Chemical Sensitization by Environmental and Occupational Agents”; Chairs- Marc Pallardy and Raymond Pieters

Symposium - “Nanoparticles for Drug Delivery: Interactions with the Immune System”; Chairs- Sandra Casinghino and Marina Dobrovolskaia

Workshop - “Therapeutic Immunomodulation and Cancer Risk: Science, Risk Assessment, and Risk Communication”; Chairs- Marc Pallardy and Shawn Heidel

Workshop - “T-Dependent Antibody Responses in Nonhuman Primates: Challenges and Opportunities”; Chairs- Jacintha Shenton and Herve Lebrec

Financial Report for 2010-2011

Submitted by: Susan McKarns

The fiscal year runs for 12 months ending on June 30th



Financial Statement	2010-2011
Income	
Contributions	-
Dues	5,010
Misc. Income	- ^a
Registration	-
Interest	513 ^b
Total Income	9.839
Expense	
Awards - Sections	(100) ^c
Plaques	759
Contribution	966
Executive Meetings	-
Miscellaneous	715 ^d
Newsletter	-
Reception	4.816
Symposia	-
Travel	-
Web Development	-
Total Expense	7,156
Excess (Deficiency) of	
Revenue over Expenses	2,683
Net Assets Beginning of year	8.081
Net Assets End of Year	10,764

Financial Report for 2009-2010

Submitted by: Susan McKarns

The fiscal year runs for 12 months ending on June 30th



Financial Statement	2009-2010
Income	
Contributions	900
Dues	5,070
Registration	3,642 ^a
Interest	385
Global Initiatives Matching Funds	2,000 ^b
Total Income	11,997
Expense	
Awards	1,550 ^c
Plaques (Accent Engraving)	760
Executive Meetings	0
Miscellaneous	1,082 ^d
Newsletter	300
Reception	9,798
Total Expense	13,490
Excess (Deficiency) of	
Revenue over Expenses	(1,493)
Net Assets Beginning of year	9,574
Net Assets End of Year	8,081

^aRegistration income reflects an allocation of funds from SOT based on the number of our members that attended the 2010 SOT Annual Meeting

^b\$2000 awarded to ImTox SS to support our International exchange with the JSIT

^c\$1000 to be credited to 2010-2011 fiscal year due to an error

^dIncludes expenses such as the ImTox Pool of Lecturer's, Student/Postdoc mixer, International Exchange, extras for the 25th Anniversary celebration

Compiled by Haley Neff-LaFord

Note: The Communications Committee has changed their policy on epub inclusion. Any article that is fully available electronically (i.e. has a doi) can now be included.

ANYTIME you have a fully published or electronically-available article to report, please send it to the coordinator, Haley Neff-LaFord: hnlaford@seagen.com

Asthma, Allergy, Autoimmunity & Hypersensitivity

de Jong HJ, Cohen Tervaert JW, Saldi SR, Vandebriel RJ, Souverein PC, Meyboom RH, van Loveren H and Klungel OH. Association between statin use and Lupus-like syndrome using spontaneous reports. *Semin Arthritis Rheum* 41:373-381, 2011.

de Jong HJ, Klungel OH, Van Dijk L, Vandebriel RJ, Leufkens HGM, van der Laan JW, Cohen Tervaert JW and van Loveren H. Use of statins is associated with an increased risk of rheumatoid arthritis. *Ann Rheum Dis* 2011 Oct 6 Epub ahead of print; PMID: 21979000, 2011.

Franko J, Jackson LG, Hubbs A, Kashon M, Meade BJ and Anderson SE. Evaluation of furfuryl alcohol sensitization potential following dermal and pulmonary exposure: enhancement of airway responsiveness. *Toxicol Sci* 125:105-115, 2012.

Hennen J, Aeby P, Goebel C, Schettgen T, Oberli A, Kalmes M and Blömeke B. Cross talk between keratinocytes and dendritic cells: impact on the prediction of sensitization. *Toxicol Sci* 123:501-510, 2011.

Johnson VJ, Reynolds JS, Wang W, Fluharty K and Yucesoy B. Inhalation of ortho-phthalaldehyde vapor causes respiratory sensitization in mice. *J Allergy (Cairo)*. 011;2011:751052. Epub 2011 Jul 14. PubMed PMID: 21785612; PubMed Central PMCID: PMC3137992.

Liu D, Zheng Y, Li B, Yao H, Li R, Zhang Y and Yang X. Adjuvant effects of gaseous formaldehyde on the hyper-responsiveness and inflammation in a mouse asthma model immunized by ovalbumin. *J Immunotoxicol* 8:305-314, 2011.

Mustafa A, Holladay SD, Witonsky S, Kerr R, Reilly C, Zimmerman K, Manari A, Countermash S and Gogal RM Jr. Prenatal TCDD causes persistent modulation of the postnatal immune response, and exacerbates inflammatory disease, in 36-week-old lupus-like autoimmune SNF1 mice. *Birth Defects Res B Dev Reprod Toxicol* 92:82-94, 2011.

Marchand LS, St-Hilaire S, Putnam EA, Serve KM and Pfau JC. Mesothelial cell and anti-nuclear autoantibodies associated with pleural abnormalities in an asbestos exposed population of Libby MT. *Toxicol Lett* 208:168-173, 2012.

Patil SD, Patel MR, Patel SR and Surana SJ. Amaranthus spinosus Linn. inhibits mast cell-mediated anaphylactic reactions. *J Immunotoxicol* 2012 early on-line DOI: 10.3109/1547691X.2011.631609.

Pot LM, Alizadeh BZ, Ahrenberg D, Coenraads PJ, Snieder H and Blömeke B. No major role for glutathione S-transferase gene polymorphisms in sensitization to para-phenylenediamine and other xenobiotics: a study of association and a meta-analysis. *Br J Dermatol* 164:890-892, 2011.

Recent Immunotoxicology Publications

Rees B, Spiekstra SW, Carfi M, Ouwehand K, Williams CA, Corsini E, McLeod JD and Gibbs S. Inter-laboratory study of the in vitro dendritic cell migration assay for identification of contact allergens. *Toxicol In Vitro* 25:2124-2134, 2011.

Shaw FL, Cumberbatch M, Kleyn CE, Begum R, Dearman RJ, Kimber I and Griffiths CEM. Langerhans cell mobilization distinguishes between early-onset and late-onset psoriasis. *J Invest Derm* 130:1940-1942, 2010.

Vandebriel RJ, Callant Cransveld C, Crommelin D, Diamant Z, Glazenburg B, Joos G, Kuper F, Natch A, Nijkamp F, Noteborn H, Pieters RD, Roggen E, Rorije E, Seed M, Sewald K, van den Heuvel R, van Engelen J, Verstraelen S and van Loveren H. Respiratory sensitization: Advances in assessing the risk of respiratory sensitization and irritation. *Toxicol in Vitro* 25:1251-1258, 2011.

Yucesoy B and Johnson VJ. Genetic variability in susceptibility to occupational respiratory sensitization. *J Allergy (Cairo)*. 011;2011:346719. Epub 2011 Jun 12. PubMed PMID: 21747866; PubMed Central PMCID: PMC3124895.

Developmental Immunotoxicology

Allina J, Grabowski J, Doherty-Lyons S, Fiel MI, Jackson CE, Zelikoff JT and Odin JA. Maternal allergy acts synergistically with cigarette smoke exposure during pregnancy to induce hepatic fibrosis in adult male offspring. *J Immunotoxicol* 8:258-264, 2011.

Holladay SD, Mustafa A and Gogal RM Jr. Prenatal TCDD in mice increases adult autoimmunity. *Reprod Toxicol* 92:82-94, 2011.

Horváthová M, Jahnová E, Palkovičová L, Trnovec T and Hertz-Pannier I. Dynamics of lymphocyte subsets in children living in an area polluted by polychlorinated biphenyls. *J Immunotoxicol* 8:333-345, 2011.

Horváthová M, Jahnová E, Palkovičová L, Trnovec T and Hertz-Pannier I. The kinetics of cell surface receptor expression in children perinatally exposed to polychlorinated biphenyls. *J Immunotoxicol* 8:367-380, 2011.

Mustafa A, Holladay SD, Witonsky S, Reilly C, Sponenberg DP and Gogal RM Jr. A single mid-gestation exposure of C57BL/6 mice to TCDD causes permanent postnatal shifts toward an autoreactive immune phenotype. *Toxicology* 290:157-169, 2011.

ul-Hassan Z, Khan MZ, Khan A, Javed I and Noreen M. In vivo and ex vivo phagocytic potential of macrophages from progeny of breeder hens kept on ochratoxin A (OTA)-contaminated diet. *J Immunotoxicol* 2012 early on-line DOI: 10.3109/1547691X.2011.635349.

ul Hassan Z, Khan MZ, Saleemi MK, Khan A, Javed I and Noreen M. Immunological responses of male White Leghorn chicks kept on ochratoxin A (OTA)-contaminated feed. *J Immunotoxicol* 2012 early on-line DOI: 10.3109/1547691X.2011.627393.

Schaalan MF, Abdelraouf SM, Mohamed WA and Hassanein FS. Correlation between maternal milk and infant serum levels of chlorinated pesticides (CP) and the impact of elevated CP on bleeding tendency and immune status in some infants in Egypt. *J Immunotoxicol* 2012 early on-line DOI: 10.3109/1547691X.2011.606432.

Effects: Compounds

Amirghofran Z, Hashemzadeh R, Javidnia K, Golmoghaddam H and Esmaeilbeig A. In vitro immunomodulatory effects of extracts from three plants of the Labiatae family and isolation of the active compound(s). *J Immunotoxicol* 8:265-273, 2011.

Banton MI, Peachee VL, White KL, Jr. and Padgett EL. Oral subchronic immunotoxicity study of ethyl tertiary butyl ether in the rat. *J Immunotoxicol* 8:298-304, 2011.

Ben Sghaier M, Krifa M, Mensi R, Bhouri W, Ghedira K and Chekir-Ghedira L. In vitro and in vivo immunomodulatory and anti-ulcerogenic activities of *Teucrium ramosissimum* extracts. *J Immunotoxicol* 8:288-297, 2011.

Carignan D, Désy O and de Campos-Lima PO. The dysregulation of the monocyte/macrophage effector function induced by isopropanol is mediated by the defective activation of distinct members of the AP-1 family of transcription factors. *Toxicol Sci* 125:144-156, 2012.

Corsini E, Sangiovanni E, Avogadro A, Galbiati V, Viviani B, Marinovich M, Galli CL, Dell'agli M and Germolec DR. In vitro characterization of the immunotoxic potential of several perfluorinated compounds (PFCs). *Toxicol Appl Pharmacol*. 2011 Nov 18. [Epub ahead of print]

Galbiati V, Carne A, Mitjans M, Galli CL, Marinovich M, Corsini E. Isoeugenol destabilizes IL-8 mRNA expression in THP-1 cells through induction of the negative regulator of mRNA stability tristetraprolin. *Arch Toxicol*. 2011 Oct 4. [Epub ahead of print] PMID: 21969073

Guilbert C, Kelly AD, Petruccelli LA, Lemaire M, Mann KK. Exposure to tungsten induces DNA damage and apoptosis in developing B lymphocytes. *Leukemia* 2011 Jun 24. doi: 10.1038/leu.2011.160. [Epub ahead of print] PMID: 21701490

Guo TL, Germolec DR, Collins BJ, Luebke RW, Auttachaoat W, Smith MJ and White KL Jr. Immunotoxicological profile of chloramine in female B6C3F1 mice when administered in the drinking water for 28 days. *J Immunotoxicol*. 8:381-388, 2011.

Hsiao CL, Wu KH and Wan KS. Effects of environmental lead exposure on T-helper cell-specific cytokines in children. *J Immunotoxicol* 8:284-287, 2011.

Inada T, Kubo K, Ueshima H and Shingu K. Intravenous anesthetic propofol suppresses prostaglandin E2 production in murine dendritic cells. *J Immunotoxicol* 8:359-366, 2011.

Katika MR, Hendriksen PJM, van Loveren H and Peijnenburg A. Exposure of Jurkat cells to bis(*tri-n*-butyltin) oxide (TBTO) induces transcriptomics changes indicative for ER- and oxidative stress, T cell activation, and apoptosis. *Toxicol Appl Pharmacol* 254:311-322, 2011.

Lu J, Jones AD, Harkema JR, Roth RA and Ganey PE. Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. *Toxicol Sci* 125:126-133, 2012.

McMahon L, Schwartz K, Yilmaz O, Brown E, Ryan LK and Diamond G. Vitamin D-mediated induction of innate immunity in gingival epithelial cells. *Infect Immun* 79:2250-2256, 2011.

Recent Immunotoxicology Publications

Nyland JF, Fairweather D, Shirley DL, Davis SE, Rose NR and Silbergeld EK. Low-dose inorganic mercury increases severity and frequency of chronic coxsackievirus-induced autoimmune myocarditis in mice. *Toxicol Sci* 125:134-143, 2012.

Nyland JF, Fillion M, Barbosa F Jr, Shirley DL, Chine C, Lemire M, Mergler D and Silbergeld EK. Biomarkers of methyl mercury exposure immunotoxicity among fish consumers in Amazonian Brazil. *Environ Health Persp* 119:1733-1738, 2011.

Palmer RK, Hutchinson LM, Burpee BT, Tupper EJ, Pelletier JH, Kormendy Z, Hopke AR, Malay ET, Evans BL, Velez A and Gosse JA. Antibacterial agent triclosan suppresses RBL-2H3 mast cell function. *Toxicol Appl Pharmacol* doi: 10.1016/j.taap.2011.10.012, 2011.

Park M, Neigh AM, Vermeulen JP, de la Fonteyne LJJ, Verharen HW, Briede JJ, van Loveren H and De Jong W. The effect of particle size on the cytotoxicity, inflammation, developmental toxicity and genotoxicity of silver nanoparticles. *Biomaterials* 32:9810-9817, 2011.

Rasmussen DL and Pfau JC. Asbestos activates CH12.LX B-lymphocytes via macrophage signaling. *J Immunotoxicol* 2012 early on-line DOI: 10.3109/1547691X.2011.631953.

Rigo I, McMahon L, Dhawan P, Christakos S, Yim S, Ryan LK and Diamond G. Induction of triggering receptor expressed on myeloid cells (TREM-1) in airway epithelial cells by 1,25(OH)2 Vitamin D3. *Innate Immun* (Epub ahead of print 2011 June 20). PMID: 21690199

Sandeep Varma R, Ashok G, Vidyashankar S, Nandakumar KS and Patki PS. Bresol inhibits phosphodiesterase 4 gene expression and modulates the levels of select mediators of inflammation in human monocytic cells. *J Immunotoxicol* 8:315-323, 2011.

Siveen KS and Kuttan G. Effect of Aerva lanata on cell-mediated immune responses and cytotoxic T-lymphocyte generation in normal and tumor-bearing mice. *J Immunotoxicol* 2012 early on-line DOI: 10.3109/1547691X.2011.609191.\

General Immunotoxicology

Buoso E, Lanni C, Molteni E, Rousset F, Corsini E and Racchi M. Opposing effects of cortisol and dehydroepiandrosterone on the expression of the receptor for Activated C Kinase 1: implications in immunosenescence. *Exp Gerontol* 46:877-883, 2011.

Heo Y, Zhang Y, Gao D, Miller VM and Lawrence DA. Aberrant immune responses in a mouse with behavioral disorders. *PLoS One* 6(7):e20912. PMID: 21799730, 2011.

Jakopin Ž, Corsini E, Gobec M, Mlinarič-Raščan I and Dolenc MS. Design, synthesis and biological evaluation of novel desmuramyldipeptide analogs. *Eur J Med Chem* 46:3762-3777, 2011.

Kalmes M, Hennen J, Clemens J and Blömeke B. Impact of aryl hydrocarbon receptor (AhR) knockdown on cell cycle progression in human HaCaT keratinocytes. *Biol Chem* 392:643-51, 2011.

Lebrec H, O'Lone R, Freebern W, Komocsar W and Moore P. Survey: Immune function and immunotoxicity assessment in dogs. *J Immunotoxicol* 2012 early on-line DOI: 10.3109/1547691X.2011.592163.

Recent Immunotoxicology Publications

Mittal N and Sanyal SN. In vivo effect of surfactant on inflammatory cytokines during endotoxin-induced lung injury in rodents. *J Immunotoxicol* 8:274-283, 2011.

Park SH, Choi HJ, Do KH, Yang H, Kim J and Moon Y. Chronic Nod2 stimulation potentiates activating transcription factor 3 and paradoxical superinduction of epithelial proinflammatory chemokines by mucoactive ribotoxic stressors via RNA-binding protein human antigen R. *Toxicol Sci* 125:116-125, 2012.

Ryan LK, Dai J, Yin Z, Megjugorac N, Uhlhorn V, Yim S, Schwartz KD, Diamond G and Fitzgerald-Bocarsly PA. Modulation of human β -defensin-1 (hBD-1) in plasmacytoid dendritic cells (PDC), monocytes and epithelial cells by influenza virus, Herpes simplex virus and Sendai virus and its possible role in innate immunity. *J Leuk Biol* 90:343-358, 2011.

Salawu MO and Oloyede OB. Endotoxin-induced coagulation reactions and phenoloxidase activity modulation in Sudanonautes africanus hemolymph fractions. *J Immunotoxicol* 8:324-332, 2011.

Zhou R, Lai Y, Yamabe N, Fukui M and Zhu BT. Estriol has different effects from 17 β -estradiol in modulating mouse splenocyte function under inflammatory conditions. *J Immunotoxicol* 8:346-358, 2011.

Methods

Dhir V, Fort M, Mahmood A, Higbee R, Warren W, Narayanan P and Wittman V. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies. *J Immunotoxicol* 2012 early on-line DOI: 10.3109/1547691X.2011.613419.

Klein SG, Hennen J, Serchi T, Blömeke B and Gutleb AC. Potential of coculture in vitro models to study inflammatory and sensitizing effects of particles on the lung. *Toxicol In Vitro* 25:1516-1534, 2011.

Marusov GP, Sweatt AJ, Pietrosimone K, Benson DR, Geary SJ, Silburt LK, Challa S, Lagoy J, Lawrence DA and Lynes M. A microarray biosensor for multiplexed detection of microbes using grating-coupled surface plasmon resonance imaging. *Environ Sci Technol* doi:10.1021/es201239f ?, 2011.

Pronk T, van der Veen J, Ezendam J, Van Loveren H and Pennings J. Effects of pooling RNA from samples treated with different compounds for determining class-specific biomarkers and processes in toxicogenomics. *Toxicol In Vitro* 25:1841-1847, 2011.

Ruwona TB, Johnson VJ, Hettick JM, Schmechel D, Beezhold D, Wang W, Simoyi RH and Siegel PD. Production, characterization and utility of a panel of monoclonal antibodies for the detection of toluene diisocyanate haptened proteins. *J Immunol Methods* 373:127-35, 2011.

Neurotoxicology

Graber DJ, Snyder-Keller A, Lawrence DA and Turner JN. Neurodegeneration by activated microglia across a nanofiltration membrane. *J Biochem Molec Toxicol* doi:10.1002/jbt.20384. PMID: 21308894, 2011.

Reviews/Workshops/Editorials

Baskettter DA and Kimber I. Assessing the potency of respiratory allergens: uncertainties and challenges. *Regul Toxicol Pharmacol* 61:365-372, 2011.

Baskettter DA and Kimber I. Skin irritation, false positives and the local lymph node assay: a guideline issue? *Regul Toxicol Pharmacol* 61:137-140, 2011.\

Baskettter D, Kimber I, van Loveren H, Pallardy M and Warheit D. Progress (from 2005-2008) and remaining gaps. In: *Progress Towards Novel Testing Strategies for in Vitro Assessment of Allergens*. Transworld Research Network, Kerala, India, pp 1-13, 2011.

Buck J, Hattersley S and Kimber I. Food allergy – science and policy needs – The UK Food Standards Agency Research Programme. *Toxicology* 278:319-325, 2010.

Corsini E, Oukka M, Pieters R, Kerkvliet NI, Ponce R and Germolec DR. Alterations in regulatory T-cells: Rediscovered pathways in immunotoxicology. *J Immunotoxicol* 8:251-257, 2011.

DeWitt J, Peden-Adams M, Keller J and Germolec D. The immunotoxicity of perfluorinated compounds: Recent developments. *Toxicol Pathol* doi: 10.1177/0192623311427709, 2011.

DeWitt J, Peden-Adams M, Keil D and Dietert R. Current status of developmental immunotoxicity: Early-life patterns and testing. *Toxicol Pathol* doi:10.1177/0192623311428473, 2011.

Diamond G, Ryan LK. β -Defensins: What are they REALLY doing in the oral cavity? *Oral Diseases* 17:628-635, 2011.

Eussen SRBM, Verhagen H, Klungel OH, Garssen J, van Loveren H, van Kranen HJ and Rompelberg CJM. Functional foods and dietary supplements: Products at the interface between pharma and nutrition. *Eur J Pharmacol* 668:52-59, 2011.

Hartung T, Blaauwboer BJ, Bosgra S, Carney E, Coenen J, Conolly RB, Corsini E, Green S, Faustman EM, Gaspari A, Hayashi M, Wallace Hayes A, Hengstler JG, Knudsen LE, Knudsen TB, McKim JM, Pfaller W and Roggen EL. An expert consortium review of the EC-commissioned report "Alternative (non-animal) methods for cosmetics testing: current status and future prospects - 2010". *ALTEX*. 28:183-209, 2011.

Kawabata T, Weaver J, Thomas D, Rowe M, Wang F, Kamperschroer C and Haggerty H. Summary of roundtable discussion meeting: Non-human primates to assess risk for EBV-related lymphomas in humans. *J Immunotoxicol* 2012 early on-line DOI: 10.3109/1547691X.2011.635166.

Ponce, RA. Safety assessment of immunomodulatory biologics: The promise and challenges of regulatory T-cell modulation. *J Immunotoxicol* 8:389-397, 2011.

van der Veen JW, Vandebriel RJ, van Loveren H and Ezendam J. Keratinocytes, Innate Immunity and Allergic Contact Dermatitis – Opportunities for the Development of In Vitro Assays to Predict the Sensitizing Potential of Chemicals. In: *Contact Dermatitis*, ImTech, 2011

Recent Immunotoxicology Publications

Vandebriel R, Callant Cransveld C, Crommelin D, Diamant Z, Glazenburg B, Joos F, Kuper F, Natsch A, Nijkamp F, Noteborn H, Pieters R, Roberts D, Roggen E, Rorije E, Seed M, Sewald K, van den Heuvel R, van Engelen J, Verstraelen S and van Loveren H. Respiratory sensitization: Advances in assessing the risk of respiratory inflammation and irritation. *Toxicol In Vitro* 25: 1251-1258, 2011.

Books/ Book Chapters

Vandebriel RJ, van Loveren H, Baken KA and Pennings JLA. Immunotoxicogenomics: A systems approach. In: General, Applied and Systems Toxicology, John Wiley & Sons, Ed. pp 1-8, 2011.